A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Galinpepimut S (Primary) ; Bortezomib; Lenalidomide; Montanide ISA-51; Sargramostim
- Indications Multiple myeloma
- Focus Pharmacodynamics
- Sponsors Sellas Life Sciences Group
- 11 Sep 2024 Status changed from active, no longer recruiting to completed.
- 06 Jan 2020 Planned End Date changed from 1 Apr 2018 to 1 Aug 2020.
- 13 Sep 2018 Results presented in a a SELLAS Life Sciences Group media release.